Sivasubramanian Baskar

Summary

Affiliation: National Institutes of Health
Country: USA

Publications

  1. pmc Antibody-based therapeutics for the treatment of human B cell malignancies
    Sivasubramanian Baskar
    Experimental Transplantation and Immunology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Curr Allergy Asthma Rep 13:33-43. 2013
  2. pmc Targeting malignant B cells with an immunotoxin against ROR1
    Sivasubramanian Baskar
    Experimental Transplantation and Immunology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA
    MAbs 4:349-61. 2012
  3. pmc Therapeutic potential and challenges of targeting receptor tyrosine kinase ROR1 with monoclonal antibodies in B-cell malignancies
    Jiahui Yang
    Experimental Transplantation and Immunology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, United States of America
    PLoS ONE 6:e21018. 2011
  4. pmc A human monoclonal antibody drug and target discovery platform for B-cell chronic lymphocytic leukemia based on allogeneic hematopoietic stem cell transplantation and phage display
    Sivasubramanian Baskar
    Experimental Transplantation and Immunology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892 1203, USA
    Blood 114:4494-502. 2009
  5. pmc Restricted cell surface expression of receptor tyrosine kinase ROR1 in pediatric B-lineage acute lymphoblastic leukemia suggests targetability with therapeutic monoclonal antibodies
    Hema Dave
    Experimental Transplantation and Immunology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    PLoS ONE 7:e52655. 2012
  6. pmc Generation, affinity maturation, and characterization of a human anti-human NKG2D monoclonal antibody with dual antagonistic and agonistic activity
    Ka Yin Kwong
    Experimental Transplantation and Immunology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    J Mol Biol 384:1143-56. 2008
  7. doi request reprint Unique cell surface expression of receptor tyrosine kinase ROR1 in human B-cell chronic lymphocytic leukemia
    Sivasubramanian Baskar
    Experimental Transplantation and Immunology Branch and Metabolism Branch, Center for Cancer Research, National Cancer Institute, and Hematology Branch, National Heart, Lung and Blood Institute, NIH, Bethesda, MD 20892 1203, USA
    Clin Cancer Res 14:396-404. 2008

Collaborators

Detail Information

Publications7

  1. pmc Antibody-based therapeutics for the treatment of human B cell malignancies
    Sivasubramanian Baskar
    Experimental Transplantation and Immunology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Curr Allergy Asthma Rep 13:33-43. 2013
    ..This review describes recent advancements in some of these adoptive immunotherapeutic strategies targeting B cell malignancies...
  2. pmc Targeting malignant B cells with an immunotoxin against ROR1
    Sivasubramanian Baskar
    Experimental Transplantation and Immunology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA
    MAbs 4:349-61. 2012
    ..Our data suggest that ROR1-immunotoxins such as BT-1 could serve as targeted therapeutic agents for ROR1-expressing B cell malignancies and other cancers...
  3. pmc Therapeutic potential and challenges of targeting receptor tyrosine kinase ROR1 with monoclonal antibodies in B-cell malignancies
    Jiahui Yang
    Experimental Transplantation and Immunology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, United States of America
    PLoS ONE 6:e21018. 2011
    ..To further assess the suitability of ROR1 for targeted therapy of CLL and MCL, a panel of mAbs was generated and its therapeutic utility was investigated...
  4. pmc A human monoclonal antibody drug and target discovery platform for B-cell chronic lymphocytic leukemia based on allogeneic hematopoietic stem cell transplantation and phage display
    Sivasubramanian Baskar
    Experimental Transplantation and Immunology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892 1203, USA
    Blood 114:4494-502. 2009
    ..Trials described herein were registered at www.clinicaltrials.gov as nos. NCT00055744 and NCT00003838...
  5. pmc Restricted cell surface expression of receptor tyrosine kinase ROR1 in pediatric B-lineage acute lymphoblastic leukemia suggests targetability with therapeutic monoclonal antibodies
    Hema Dave
    Experimental Transplantation and Immunology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    PLoS ONE 7:e52655. 2012
    ..The receptor tyrosine kinase ROR1 has emerged as a candidate for mAb targeting in select B-cell malignancies...
  6. pmc Generation, affinity maturation, and characterization of a human anti-human NKG2D monoclonal antibody with dual antagonistic and agonistic activity
    Ka Yin Kwong
    Experimental Transplantation and Immunology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    J Mol Biol 384:1143-56. 2008
    ..By contrast, immobilized KYK-2.0 IgG1 was found to strongly induce human NK cell activation. The dual antagonistic and agonistic activity promises a wide range of therapeutic applications for KYK-2.0 IgG1 and its derivatives...
  7. doi request reprint Unique cell surface expression of receptor tyrosine kinase ROR1 in human B-cell chronic lymphocytic leukemia
    Sivasubramanian Baskar
    Experimental Transplantation and Immunology Branch and Metabolism Branch, Center for Cancer Research, National Cancer Institute, and Hematology Branch, National Heart, Lung and Blood Institute, NIH, Bethesda, MD 20892 1203, USA
    Clin Cancer Res 14:396-404. 2008
    ..To assess the suitability of ROR1 as a cell surface antigen for targeted therapy of B-CLL, we carried out a comprehensive analysis of ROR1 protein expression...